CLX

Business profile & competitive position

The Clorox Company is a multinational manufacturer and marketer of consumer and professional products, operating under the Consumer Defensive sector and the Household & Personal Products industry. Its fiscal 2026 net sales reached $6.7 billion, generated by roughly 9,200 employees across approximately 25 countries and sold into about 95 markets. The brand roster spans Clorox bleach and disinfectants, Pine-Sol, Glad, Fresh Step, Kingsford charcoal, Hidden Valley, Brita, and Burt’s Bees, while the professional segment markets Purell, CloroxPro, and Clorox Healthcare products.

Competitive positioning in household products usually rests on brand equity, distribution scale, and pricing power, but the raw numbers add important texture. Clorox’s net margin of 8.7% is mediocre for a portfolio of leading brands, suggesting that cost inflation, promotional intensity, and mix shifts have compressed profitability. More striking is the ROE of -1893.5%, which does not reflect operational losses at that magnitude but rather a balance-sheet structure where liabilities exceed equity. In practical terms, the company has been returning capital to shareholders and carrying leverage while earnings are positive but lower than in prior periods. That combination means the moat is still real—consumers recognize its brands and Walmart alone booked 26% of FY2026 net sales—but the economics are strained.

Financial posture

Clorox currently carries an $11.8 billion market capitalization and trades at a P/E of 20.3. Its beta is 0.54, consistent with the low-volatility, household-staples profile most investors associate with the Consumer Defensive sector. The 8.7% net margin and negative ROE tell two different stories: operations are still profitable, but equity is deeply negative. When ROE is distorted by the shareholders’ deficit, P/E and margin trend matter more than the headline ROE itself.

Leverage is the key variable here. A negative equity base implies debt-funded operations and aggressive capital return, which is sustainable only if free cash flow remains stable and refinancing conditions stay manageable. At the current price of $97.96, CLX sits below its 50-day EMA of $101.20, with an RSI of 37.8—near the lower end of neutral but not yet oversold. The valuation is neither deep-value nor expensive relative to many staples peers; the more relevant question is whether margins can recover while the company integrates a major acquisition and overhauls its ERP backbone.

Strategic priorities & outlook

Clorox’s most recent 10-K frames the near-term agenda around the IGNITE strategy. The four stated choices are: fuel long-term profitable growth, innovate consumer experiences, reimagine how the company and its people work, and continuously evolve the product portfolio. Operationally, that translates into completing and optimizing a new enterprise resource planning (ERP) system and broader digital transformation, with the goal of generating long-term efficiencies across supply chain, digital commerce, innovation, and brand building.

Portfolio moves are equally prominent. In April 2026, Clorox completed the acquisition of GOJO Industries, adding Purell to the health and hygiene lineup and deepening the business-to-business channel. Management also emphasizes advancing health and hygiene expansion, integrating GOJO, and capturing growth in professional and institutional markets. The 10-K explicitly notes that FY2026 organic sales and earnings declined, with diluted EPS down 26%, partly because macroeconomic headwinds persisted and because ERP transition timing had pulled some sales into fiscal 2025. Another structural change is the January 31, 2026 expiration of the Glad bags and wraps venture with P&G, after which Clorox bought P&G’s 20% interest and retained core intellectual property licenses on a royalty-free basis. The immediate risk is execution noise; the longer-term objective is a more resilient, consistently profitable company built on strong brands and a streamlined operating model.

Macro & geopolitical exposure

As a Household & Personal Products company, Clorox is exposed to a set of macro forces that affect nearly every peer in the sector. Input costs for resins, chemicals, packaging materials, and transportation can move sharply with energy and commodity cycles, pressuring gross margins even when volumes hold steady. Currency risk is meaningful for a company selling in roughly 95 markets, because a stronger U.S. dollar reduces the reported value of overseas revenue and profits.

Demand itself is defensive but not recession-proof; private-label competition tends to intensify when household budgets tighten. Regulatory exposure is another constant: cleaning agents, disinfectants, food-contact products, and personal-care items face evolving safety, labeling, and environmental rules. Supply-chain resilience—especially for concentrated retail customers—remains a headline sensitivity, as does the bargaining power of a consolidated retail landscape. None of these are unique to Clorox, but they define the sandbox in which the company must execute its integration and margin-recovery plans.

Recent developments

Recent news flow has been light on operational updates and heavy on ownership and income-focused coverage. On August 31, 2026, defenseworld.net reported that the Canada Pension Plan Investment Board acquired 32,488 shares of CLX. Five days earlier, on August 26, YouTube content highlighted “3 Cheap Stocks Offering Attractive Income.” August 24 brought two items: a Motley Fool piece asking whether passive income investors should buy Clorox stock, and a defenseworld.net report that Barrow Hanley Mewhinney & Strauss LLC purchased 106,377 shares.

The institutional accumulation headlines suggest that at least some long-horizon buyers find current valuation levels interesting, while the income-oriented articles point to the dividend profile that staples investors traditionally watch. Taken together, the news does not point to a specific catalyst; it points to a stock that is being evaluated as a defensive, cash-flow-oriented holding. Against that backdrop, price action and the broader technical setup remain the near-term focal points.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Clorox has beaten the consensus EPS estimate six times, for a beat rate of 75%. The average earnings surprise across those quarters is 9.4%, indicating that estimates have generally undervalued the company’s earnings power. The average five-day price move after earnings is +1.67%, classified as an upward post-earnings drift. That said, the individual episodes show how noisy the reaction can be.

The most recent report, on August 3, 2026, delivered $1.66 versus the $1.64 consensus, a modest 1.2% surprise, yet the stock jumped 6.52% the next day and 9.61% over the following five sessions. By contrast, the prior quarter—April 30, 2026—saw a 5.8% beat on $1.64 versus $1.55, but the stock fell 9.67% the next day and was down 4.49% five sessions later. The February 3, 2026 miss of -2.8% ($1.39 versus $1.43) paradoxically produced a 2.43% next-day gain and a 5.63% five-day advance, while the November 3, 2025 report beat by 3.9% ($0.85 versus $0.818) and still drifted -4.08% over the next week.

Looking ahead, Clorox next reports after the close on November 3, 2026, with the current consensus EPS estimate at $1.11. The historical beat rate and positive average drift are notable, but the wide dispersion of post-earnings moves means the reaction function may depend on guidance, margin commentary, and GOJO integration detail rather than the headline number alone.

For a deeper dive into institutional sentiment, price targets, and the full consensus distribution around the upcoming report, explore the complete institutional verdict on CLX.